

Join a Clinical Trial



NORTHERN
CANCER
INSTITUTE



You are invited to participate in a research study into the effect of a probiotic formulation for the prevention of diarrhoea and other gut upsets in patients having chemotherapy.

The study is being conducted with Professor Stephen Clarke, Medical Oncologist at the Northern Cancer Institute.

The aim of the study is to examine if taking a specially formulated probiotic (Medlab MultiBiotic™) may have beneficial effect on the microbiome and improve intestinal health during chemotherapy.

As an appreciation of your participation in the study you will continue to receive probiotics from the study sponsor for the duration of your treatment with your oncology specialist.

During the study you will be required to provide on two occasions a small faecal and blood sample during your chemotherapy treatment. You will also be required to fill out a patient diary at certain times.

Interested?

Please request the information sheet from the nurses

Clinical Trial Title

The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea/neutropenia: an exploratory end-point pilot study.

For further information, please contact the Clinical Trial Coordinators
Daniel O'Connor: 0433 826 304 or daniel_oconnor@medlab.co
Michael Thomsen: 0438 700 287 or mtho0952@uni.sydney.edu.au

MultiBiotic™
Patented multi-species probiotic scientifically formulated to improve gut health



MultiBiotic™ is an evidence-based multi-species probiotic specifically designed to target end-organ function and support gastrointestinal health and maintenance.

MultiBiotic™ is designed to rescue a dysbiotic state associated with antibiotic use, assisting with side effects such as diarrhoea.¹ MultiBiotic™ also assists in managing symptoms of medically diagnosed Irritable Bowel Syndrome, relieving altered bowel habits and gastrointestinal discomfort.² Formulated by Medlab researchers, MultiBiotic™ has undergone murine research and is currently undergoing human research for non-alcoholic fatty liver disease (NAFLD).

"Different strains with different characteristics have an enhanced chance of colonisation"

ACTIVE INGREDIENTS:	Each Capsule Contains:
Lactobacillus rhamnosus (Med 26)	9 billion
Lactobacillus acidophilus (Med 27)	3.75 billion
Lactobacillus plantarum (Med 25)	1.575 billion
Bifidobacterium animalis ssp. lactis (Med 13)	3 billion
Bifidobacterium breve (Med 12)	1.75 billion
Bifidobacterium bifidum (Med 11)	500 million
Streptococcus thermophilus (Med 51)	1.5 billion
Total	21.075 Billion CFU* (1 capsule)
	42.15 Billion CFU* (2 capsules)

*CFU: Colony Forming Units
Excipients: Maltodextrin (potato), silica, magnesium stearate.

DOSAGE GUIDELINES:
Adult Recommended Dose:
Take 1-2 capsule(s) morning and night with water before meals or as directed by your healthcare professional.
AUST L 227562

AVAILABLE IN 30 & 60 CAPSULES

DAIRY & GLUTEN FREE

VEGETARIAN FRIENDLY

SMALL SIZED CAPSULES

FOR PROFESSIONAL USE ONLY



*Reference: H.M. Timmerman et al (2004). International Journal of Food Microbiology 96, 219-235